Linezolid for drug-resistant pulmonary tuberculosis

Singh, Bhagteshwar, Cocker, Derek, Ryan, Hannah and Sloan, Derek (2019) 'Linezolid for drug-resistant pulmonary tuberculosis'. Cochrane Database of Systematic Reviews, Vol 3, CD012836.

Preview

Text Singh_et_al-2019-Cochrane_Database_of_Systematic_Reviews.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (895kB) | Preview

Abstract

Linezolid was recently re‐classified as a Group A drug by the World Health Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining unclear. Current guidelines are mainly based on evidence from observational non‐comparative studies.

Item Type:	Article
Subjects:	WA Public Health > Statistics. Surveys > WA 950 Theory or methods of medical statistics. Epidemiologic methods WF Respiratory System > Tuberculosis > WF 200 Tuberculosis (General) WF Respiratory System > Tuberculosis > WF 310 Therapy WF Respiratory System > Tuberculosis > WF 360 Drug therapy
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department Clinical Sciences & International Health > International Public Health Department
Digital Object Identifer (DOI):	https://doi.org/10.1002/14651858.cd012836.pub2
SWORD Depositor:	JISC Pubrouter
Depositing User:	Stacy Murtagh
Date Deposited:	29 Mar 2019 09:29
Last Modified:	04 Apr 2019 14:21
URI:	https://archive.lstmed.ac.uk/id/eprint/10542

Statistics

View details

Actions (login required)

Edit Item